Nolpaza (Pantoprazole)

Pantoprazole, the active ingredient in Nolpaza, is a proton pump inhibitor presented as an injectable solution for intravenous use. It reduces gastric acid secretion and is employed in the treatment of gastro‑esophageal reflux disease, erosive esophagitis, peptic ulcer disease, and for stress ulcer prophylaxis in hospitalized patients.

GNH USA supplies Nolpaza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution.

Pantoprazole, a proton pump inhibitor, is used to manage acid‑related gastrointestinal disorders. - Gastro‑esophageal reflux disease (GERD): reduces acid exposure, alleviating heartburn and promoting esophageal healing. - Erosive esophagitis: decreases gastric acid secretion, allowing damaged esophageal tissue to recover. - Peptic ulcer disease: suppresses acid production, supporting ulcer healing and preventing recurrence. - Stress ulcer prophylaxis: provides acid suppression in critically ill or hospitalized patients at risk of stress‑related gastric lesions.

Pantoprazole may be associated with a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools that may be self‑limiting. - Nausea: occasional feeling of queasiness. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile infection: severe colitis associated with antibiotic use. - Hepatic enzyme elevation: significant increase in liver transaminases. - Stevens‑Johnson syndrome: rare but life‑threatening skin reaction.

When prescribing or administering Pantoprazole, several precautionary measures should be considered to ensure safe use. - Renal impairment: monitor renal function and adjust therapy if necessary. - Hepatic impairment: use with caution and observe liver function tests. - Elderly patients: assess for electrolyte disturbances and dehydration. - Concomitant anticoagulants: monitor coagulation parameters such as INR. - Pregnancy and lactation: prescribe only if potential benefit justifies potential risk. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Pantoprazole can interact with other medicines, affecting their efficacy or safety.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet activity. - Atazanavir: decreased absorption and therapeutic effect. - Methotrexate: increased systemic exposure and toxicity. - Warfarin: enhanced anticoagulant effect, monitor INR closely. - Ketoconazole: reduced absorption due to increased gastric pH.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum concentrations. - Phenytoin: decreased plasma levels. - Diazepam: elevated levels may occur.